{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:52:04Z","timestamp":1788209524400,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Azathioprine (AZA) interferes with the activation of T and B lymphocytes, which are the main cells involved in the pathogenesis of Graves\u2019 disease (GD). The aim of this study was to investigate the effectiveness of AZA as an adjuvant therapy to antithyroid drugs (ATDs) for moderate and severe GD. In addition, we conducted an incremental cost-effectiveness analysis of AZA to determine its cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a randomized, open-label, and parallel-group clinical trial. We randomized untreated hyperthyroid patients with severe GD into three groups. All patients received 45-mg carbimazole (CM) as the starting dose and propranolol 40\u2013120 mg daily. The first group (AZA1) received an additional 1 mg\/kg\/day AZA, the second group (AZA2) received an additional 2 mg\/kg\/day AZA, and the third group (control group) received only CM and propranolol. We measured thyroid-stimulating hormone (TSH) and TSH-receptor antibody (TRAb) levels at baseline and every 3 months, while free triiodothyronine (FT3) and free thyroxine (FT4) levels were measured at the time of diagnosis, 1 month after initiation of therapy, and every 3 months thereafter until 2 years after remission. Thyroid volume (TV) was assessed by ultrasound at baseline and 1 year after remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 270 patients were included in this trial. By the end of follow-up, there was higher remission rate in the AZA1 and AZA2 groups compared with controls (87.5% and 87.5%\n                      <jats:italic>vs<\/jats:italic>\n                      . 33.4%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002). Throughout the course of follow-up, FT3, FT4, TSH, and TRAb were significantly different between the AZA groups and the control group, but there was no significant difference regarding TV. The decline in the concentrations of FT4, FT3, and TRAb was significantly faster in the AZA2 group than in the AZA1 group. The relapse rate during the 12-month follow-up was insignificantly higher in the control group than in either the AZA1 or AZA2 group (10, 4.4, and 4.4%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.05, respectively). The median relapse time was 18 months for the control group and 24 months for the AZA1 and AZA2 groups. The incremental cost-effectiveness ratio for the AZA group compared with the conventional group was 27,220.4 Egyptian pounds per remission reduction for patients using AZA as an adjuvant for ATDs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AZA could be a novel, affordable, cost-effective, and safe drug offering hope for patients with GD to achieve early and long-lasting medical remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registry<\/jats:title>\n                    <jats:p>The trial is registered at the Pan African Clinical Trial Registry (Registration number: PACTR201912487382180).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2023.1168936","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T06:25:53Z","timestamp":1687242353000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Azathioprine as an adjuvant therapy in severe Graves\u2019 disease: a randomized controlled open-label clinical trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Magdy Mohamed","family":"Allam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanaa Tarek","family":"El-Zawawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr Abdel","family":"Kader Okda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoub","family":"Ali Alshaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy Mohamed","family":"Ghazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00521","article-title":"Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases","volume":"8","author":"Fr\u00f6hlich","year":"2017","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves' disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2017.14476","article-title":"Personalised immunomodulating treatments for graves\u2019 disease: fact or fiction","volume":"147","author":"Struja","year":"2017","journal-title":"Swiss Med Weekly"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60782-4","article-title":"Thyrotoxicosis","volume":"379","author":"Franklyn","year":"2012","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/EJE-07-0450","article-title":"TSH-receptor autoimmunity in graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study","volume":"158","author":"Laurberg","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/thy.2006.16.295","article-title":"Serum thyrotropin receptor antibodies concentrations in patients with graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and\/or thyroid response modify during the observation period","volume":"16","author":"Carella","year":"2006","journal-title":"Thyroid"},{"key":"B7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12902-020-00551-2","article-title":"Predictors of euthyreosis in hyperthyroid patients treated with radioiodine 131I\u2013: a retrospective study","volume":"20","author":"Stachura","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005474","article-title":"Time course of graves' orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer","volume":"95","author":"Louvet","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0218","article-title":"Glucocorticoid regimens for prevention of graves' ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis","volume":"24","author":"Shiber","year":"2014","journal-title":"Thyroid"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000508789","article-title":"Novel approaches for immunosuppression in graves\u2019 hyperthyroidism and associated orbitopathy","volume":"9","author":"Lee","year":"2020","journal-title":"Eur Thyroid J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25158414211027760","DOI":"10.1177\/25158414211027760","article-title":"Updates on the understanding and management of thyroid eye disease","volume":"13","author":"Men","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1530\/acta.0.1220008","article-title":"Azathioprine in the treatment of thyroid-associated ophthalmopathy","volume":"122","author":"Perros","year":"1990","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000923","article-title":"Experts opinion on the practical use of azathioprine and 6-mercaptopurine in inflammatory bowel disease","volume":"22","author":"Mottet","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0647","article-title":"Does immunosuppressive therapy improve outcomes in graves' disease? a systematic review and meta-analysis","volume":"26","author":"Struja","year":"2016","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/ccr3.1827","article-title":"Induction of remission in autoimmune polyglandular syndrome type three (APS III): an old drug with new perspectives","volume":"6","author":"Allam","year":"2018","journal-title":"Clin Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0613","article-title":"Rapid remission of graves' hyperthyroidism without thionamides under immunosuppressive treatment for concomitant autoimmune hepatitis","volume":"28","author":"Papadakis","year":"2018","journal-title":"Thyroid"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.72352","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"1","author":"Schulz","year":"2010","journal-title":"J Pharmacol Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension","volume":"328","author":"Butcher","year":"2022","journal-title":"Jama"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862831","article-title":"New therapeutic horizon of graves\u2019 hyperthyroidism: treatment regimens based on immunology and ingredients from traditional Chinese medicine","volume":"13","author":"He","year":"2022","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000511871","article-title":"Modulating TSH receptor signaling for therapeutic benefit","volume":"9","author":"Krause","year":"2020","journal-title":"Eur Thyroid J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa022","article-title":"New therapeutic horizons for graves\u2019 hyperthyroidism","volume":"41","author":"Lane","year":"2020","journal-title":"Endocr Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2135","article-title":"Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by graves\u2019 disease","volume":"92","author":"Nakamura","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.3.6430","article-title":"Age and gender predict the outcome of treatment for graves\u2019 hyperthyroidism","volume":"85","author":"Allahabadia","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0085","article-title":"The long-term outcome of treatment for graves' hyperthyroidism","volume":"29","author":"Sj\u00f6lin","year":"2019","journal-title":"Thyroid"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346433","article-title":"Long-term follow-up of patients with hyperthyroidism due to graves\u2019 disease treated with methimazole. comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study","volume":"31","author":"Mazza","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.369","article-title":"Clinical features of patients with graves' disease undergoing remission after antithyroid drug treatment","volume":"7","author":"Vitti","year":"1997","journal-title":"Thyroid"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K06-069","article-title":"Prognostic value of thyrotropin receptor antibodies (TRAb) in graves' disease: a 120 months prospective study","volume":"54","author":"Cappelli","year":"2007","journal-title":"Endocr J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5945178","article-title":"Predictors of initial and sustained remission in patients treated with antithyroid drugs for graves\u2019 hyperthyroidism: the RISG study","volume":"2019","author":"Karmisholt","year":"2019","journal-title":"J Thyroid Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"20420188211044943","DOI":"10.1177\/20420188211044943","article-title":"The prognostic value of thyroid-stimulating immunoglobulin in the management of graves\u2019 disease","volume":"12","author":"Zhou","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac252","article-title":"Future projections in thyroid eye disease","volume":"107","author":"Barbesino","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4103\/ijmbs.ijmbs_75_18","article-title":"Predictors of relapse in graves' hyperthyroidism after treatment with antithyroid drugs","volume":"10","author":"Lawgaly","year":"2018","journal-title":"Ibnosina J Med Biomed Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00554.x","article-title":"Is there a methimazole dose effect on remission rate in graves' disease? results from a long-term prospective study","volume":"49","author":"Benker","year":"1998","journal-title":"Clin Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1507\/endocrine1927.66.5_543","article-title":"The prognostic application of thyroid volume determination in patients with graves' disease","volume":"66","author":"Sakane","year":"1990","journal-title":"Nihon Naibunpi Gakkai Zasshi"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2020.05.003","article-title":"Azathioprine: its uses in dermatology","volume":"95","author":"Chavez-Alvarez","year":"2020","journal-title":"Anais Brasileiros de Dermatologia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1555759","article-title":"Outcome prediction of treatment of graves\u2019 hyperthyroidism with antithyroid drugs","volume":"47","author":"Piantanida","year":"2015","journal-title":"Hormone Metab Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1168936\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T06:25:58Z","timestamp":1687242358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1168936\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":36,"alternative-id":["10.3389\/fendo.2023.1168936"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1168936","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"article-number":"1168936"}}